Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Chemo-immunotherapy became the standard of care in the first-line treatment of ES-SCLC after the IMpower133 trial demonstrated an improvement in overall survival with carboplatin/etoposide (CP/ET) + atezolizumab (atezo). This exploratory analysis seeks to examine patterns of first progression after CP/ET + atezo in IMpower133 (NCT02763579).